Chi-Med appoints Dr Weiguo Su, Chief Scientific Officer, to Board of Directors
March 24 2017 - 3:30AM
Business Wire
Hutchison China MediTech Limited (“Chi-Med” or the “Company”)
(AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been
appointed as Executive Director and member of Technical Committee
with effect from March 27, 2017.
Dr Su, aged 59, has been the Executive Vice President and Chief
Scientific Officer of the Company since 2012. Dr Su has headed all
drug discovery and research since he joined the Company, including
master-minding the Company’s scientific strategy, being a key
leader of the Innovation Platform, and responsible for the
discovery of each and every small molecule drug candidate in the
Company’s product pipeline. Prior to joining the Company in 2005,
Dr Su spent 15 years with the U.S. Research and Development
Department of Pfizer, Inc. with his last position as director of
the Medicinal Chemistry Department.
In March 2017, Dr Su was granted the prestigious award by the
China Pharmaceutical Innovation and Research Development
Association (PhIRDA) as one of the Most Influential Drug R&D
Leaders in China.
Dr Su received a Bachelor of Science degree in Chemistry from
Fudan University in Shanghai. He completed a PhD and Post-doctoral
Fellowship in Chemistry at Harvard University under the guidance of
Nobel Laureate Professor E. J. Corey.
Dr Su holds 51,070 American depository shares and 300,000 share
options in Chi-Med. Save for the information disclosed above, there
is no other information in relation to Dr Su that is required to be
disclosed pursuant to Rule 17 and Schedule 2(g) of the AIM Rules
for Companies.
Mr Simon To, Chairman of Chi-Med said “We welcome Dr Su to the
Board. His experiences in the global biopharmaceutical industry
will be important to the Company.”
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med’s current expectations regarding future
events. Forward-looking statements involve risks and uncertainties.
Such risks and uncertainties include, among other things, the risk
that current or future appointees to Chi-Med’s board of directors
are not effective in their respective positions, the difficulty in
locating and recruiting suitable candidates for its board of
directors and the management difficulties which may arise from
changes in Chi-Med’s board of directors. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
For further discussion of these and other risks, see Chi-Med’s
filings with the U.S. Securities and Exchange Commission and on
AIM. Chi-Med undertakes no obligation to update or revise the
information contained in this announcement, whether as a result of
new information, future events or circumstances or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170324005153/en/
Investor EnquiriesChristian Hogg, CEO+852 2121
8200orInternational Media EnquiriesAnthony Carlisle,
Citigate Dewe Rogerson+44 7973 611 888
(Mobile)anthony.carlisle@cdrconsultancy.co.ukorU.S. Based Media
EnquiriesBrad Miles, BMC Communications+1 (917) 570 7340
(Mobile)bmiles@bmccommunications.comorSusan Duffy, BMC
Communications+1 (917) 499 8887
(Mobile)sduffy@bmccommunications.comorInvestor RelationsMatt
Beck, The Trout Group+1 (917) 415 1750
(Mobile)mbeck@troutgroup.comorDavid Dible, Citigate Dewe
Rogersondavid.dible@citigatedr.co.uk+44 7967 566 919
(Mobile)orPanmure Gordon (UK) LimitedRichard Gray / Andrew
Potts+44 (20) 7886 2500
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024